Chemoresection may be a minimally invasive option for recurrent Ta, intermediate-risk non-muscle-invasive bladder cancer (NMIBC).

A TURBT allows examination beyond the bladder. Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for ...

Receiving a diagnosis of stage 1 urothelial carcinoma (bladder cancer) can feel overwhelming, but at this stage, the cancer ...

A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Background: Frail and elderly patients ...

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses. Patients with recurrent low-grade intermediate-risk ...

Secondary analysis of PURE-01: Role of FDG-PET/CT in evaluating lymph node involvement of patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant pembrolizumab and radical cystectomy ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Transurethral Resection of Bladder Tumor, or TURBT, is a procedure that allows your surgeon to biopsy or remove a tumor from the inside of your bladder while leaving the bladder intact. Because the ...

Bladder cancer is the seventh most common cancer in men, with nearly 400,000 cases diagnosed per year. However, despite the use of transurethral resection of the bladder tumor (TURBT), a large number ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...